Eli Lilly Launches Rezvoglar as Second Interchangeable Insulin Biosimilar in the US
Shots:
- The company launched Rezvoglar, a second interchangeable biosimilar insulin product to Lantus (insulin glargine) in the US market for the treatment of patients with diabetes. Rezvolgar will launch at a 78% discount to the reference Lantus
- Insulin glargine products are used to improve glycemic control in adult and pediatric patients with T1D and in adults with T2D. Additonally, Rezvoglar was also approved in the US on Nov 2022
- In addition to Rezvoglar, Lilly is the owner of Humulin (recombinant human insulin), Humalog (reference insulin lispro), as well as an unbranded insulin lispro product
Ref: Center For Bioimilars | Image: Eli Lilly
Related News:- Eli Lilly Presents P-III Clinical Development Program Results of Lebrikizumab for Atopic Dermatitis at 5th Annual RAD Congress
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
